LINC01139 and triple-negative breast carcinoma: In triple-negative breast cancer (TNBC) of patients receiving pembrolizumab (anti-PD-1) treatment, the pembrolizumab responders exhibited a relatively lower expression of LINK-A and a higher CD8+ T cell infiltration compared with non-responders (45), concluding that the CD8+ T cell infiltration in TNBC is negatively correlated with LINK-A expression (45).